Which FDA-approved product is used for seizures greater than 2 years old due to specific syndromes?

Epidiolex is the FDA-approved product specifically indicated for the treatment of seizures associated with certain severe forms of epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome, in patients aged 2 years and older. This product is a cannabidiol oral solution that has undergone rigorous clinical trials and has demonstrated significant efficacy in reducing seizure frequency in these specific syndromes.

Epidiolex stands out because it is derived from cannabis but does not have the psychoactive effects commonly associated with marijuana. The FDA approval for Epidiolex marks a pivotal point in the treatment landscape for pediatric epilepsy by offering a non-synthetic option tailored for children with difficult-to-treat conditions.

Other choices, while they may have relevance in the context of seizures or cannabinoid treatments, do not have the same specific indications approved for use in patients over the age of 2 with particular seizure syndromes. For instance, Nabilone and Dronabinol are primarily used in conditions such as nausea and vomiting associated with chemotherapy or anorexia in weight loss, rather than for seizure disorders. Gabapentin is an anticonvulsant that is often used for neuropathic pain and seizures; however, it does not have the same indication for severe syndromes as Epid